Animal studies and research in humans have shown that the supplementation of tyrosine, or tyrosinecontaining diets, increase the plasma tyrosine and enhance brain dopamine (DA). However, the strategy of administering tyrosine (and the role of DA therein) to enhance cognition is unclear and heavily debated. We studied, in a healthy population, whether tyrosine supplementation improves stopping overt responses, a core cognitive-control function. In a double-blind, placebo-controlled, within-subject design, one hour following the administration of tyrosine (corresponding to the beginning of the 1 hpeak of the plasma concentration) or placebo, participants performed a stop-signal task-which taps into response inhibition and response execution speed. Participants in the Tyrosine condition were more efficient in inhibiting unwanted action tendencies but not in reacting to go signals. This is the first demonstration that the supplementation of tyrosine selectively targets, and reliably improves the ability to stop overt responses.
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Introduction
Tyrosine is one of the most investigated amino acids, the building blocks of proteins. It is contained in food such as fish, soy, eggs, milk and bananas, and it is the precursor (the chemical that precedes another compound in the biochemical pathway) of the neurochemical dopamine (DA). Animal studies and research in humans have shown that the supplementation of tyrosine, or tyrosine-containing diets, increase the plasma tyrosine and enhance brain DA release, in particular from activated neurons (Acworth, During, & Wurtman, 1988; During, Acworth, & Wurtman, 1988; see Deijen, 2005 , for a comprehensive review). Even though the neurobiology of tyrosine supplementation is not yet completely understood, this phenomenon does not seem to be subject to dose-dependent effects (Deijen & Orlebeke, 1994; Shurtleff, Thomas, Schrot, Kowalski, & Harford, 1994) . This indicates that the relation between tyrosine and cognitive performance does not follow the inverted U-shaped dose-effect curve that is typical for dopaminergic agonists (Cools, 2006) . Once the optimal level is reached, higher levels of tyrosine will thus no longer increase DA levels, as the enzyme tyrosine hydroxylase, which converts tyrosine into DA, will be inhibited (Gibson & Wurtman, 1977) . Therefore, even excessive levels of tyrosine administration are not expected to impair cognitive processes.
Previous literature has mainly focused on the supplementation of tyrosine to reverse conditions associated with dopaminergicbased pathologies, such as Parkinson 0 s disease (Growdon, Melamed, & Logue, 1982; Lemoine, Robelin, Sebert, & Mouret, 1989 ), phenylketonuria (van Spronsen, van Dijk, & Smit, 1996 , depression (Gelenberg, Wojcik, Gibson, & Wurtman, 1983; Gelenberg & Gibson, 1984; Gelenberg, Wojcik, & Falk, 1990 ) and attention deficit disorder (Wood, Reimherr, & Wender, 1985; Reimherr, Wender, Wood, & Ward, 1987) . Furthermore, the role of tyrosine as "counteractor" has been largely investigated under conditions that cause brain DA depletion, such as stress. In humans, tyrosine has been shown to reverse stress-induced deficits in working memory and attentional tasks (Deijen & Orlebeke, 1994; Shurtleff et al., 1994; Mahoney, Castellani, & Kramer, 2007) . Only in one study tyrosine has been administered without exposure to stress, revealing beneficial effects, but only when performing more tasks at the same time (Thomas, Lockwood, Sing, & Deuster, 1999) . This indicates that tyrosine may reverse "ego-depletion" (Baumeister, Bratslavsky, Muraven, & Tice, 1998) (i.e. reduced self-control after a depleting task), but only when cognitive control is required. This should not be 
